⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25410167 | 0.80 | — | — | |
| SCHEMBL10957711 | 0.74 | — | — | |
| SCHEMBL5134164 | 0.74 | IL1B (0.45) | — | |
| SCHEMBL15850527 | 0.73 | — | — | |
| SCHEMBL20929052 | 0.73 | — | — | |
| SCHEMBL1974907 | 0.73 | — | — | |
| SCHEMBL6822905 | 0.73 | — | — | |
| SCHEMBL4837697 | 0.73 | — | — | |
| SCHEMBL1973618 | 0.73 | — | — | |
| SCHEMBL12943882 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2025057114-A1 | PARP1 INHIBITORS AND THE USE IN THE TREATMENT OF CNS DISEASES | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4490161-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119013279-A | Substituted tricyclic compounds as PARP inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230348473-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348473-A1 | SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS | XINTHERA, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023212219-A1 | TRICYCLIC PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11795173-B1 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795173-B1 | Substituted pyridines as PARP1 inhibitors | XINTHERA, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023169226-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |